EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system

Michael P Moazami, Julia M Rembetsy-Brown, Samantha L Sarli, Holly R McEachern, Feng Wang, Masahiro Ohara, Atish Wagh, Karen Kelly, Pranathi Meda Krishnamurthy, Alexandra Weiss, Miklos Marosfoi, Robert M King und 5 weitere

Molecular Therapy · 2024

DOI: 10.1016/j.ymthe.2024.10.024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Therapy, 2024. Verfasst von Michael P Moazami und 16 weiteren Autor:innen. Beteiligte Einrichtung: RNA Therapeutics Institute, UMass Chan Medical School, Worcester, MA 01605 USA. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, Phenotype. Die Arbeit wurde bisher 34-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, National Institute of Neurological Disorders and Stroke, Ono Pharma Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antisense oligonucleotides (ASOs) are emerging as a promising class of therapeutics for neurological diseases. When injected directly into cerebrospinal fluid, ASOs distribute broadly across brain regions and exert long-lasting therapeutic effects. However, many phosphorothioate (PS)-modified gapmer ASOs show transient motor phenotypes when injected into the cerebrospinal fluid, ranging from reduced motor activity to ataxia or acute seizure-like phenotypes. Using a behavioral scoring assay customized to reflect the timing and nature of these effects, we show that both sugar and phosphate modifications influence acute motor phenotypes. Among sugar analogs, DNA induces the strongest motor phenotypes while 2'-substituted RNA modifications improve the tolerability of PS ASOs. Reducing the PS content of gapmer ASOs, which contain a stretch of PS-DNA, improves their toxicity profile, but in some cases also reduces efficacy or duration of effect. We show that this acute toxicity is not mediated by major nucleic acid sensing immune pathways. Formulating ASOs with divalent ions before injection and avoiding phosphate-based buffers modestly improved tolerability through mechanisms at least partially distinct from reduced PS content. Overall, our work identifies and quantifies an understudied aspect of oligonucleotide toxicology in the CNS, explores its mechanism, and presents platform-level medicinal chemistry and formulation approaches that improve tolerability of this class of compounds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oligonucleotides, AntisensePhenotypeAnimalsMiceCentral Nervous SystemMaleHumansPhosphorothioate OligonucleotidesMotor Activity

Stichwörter der Autor:innen

CNS deliveryantisense therapeuticsartificial CSFgapmer ASOsneurotherapeuticsneurotoxicityoligonucleotidesphosphate bufferphosphorothioatetoxicology

Substanzen

Oligonucleotides, AntisensePhosphorothioate Oligonucleotides

Autor:innen und Institutionen

  • RNA Therapeutics Institute, UMass Chan Medical School, Worcester, MA 01605 USA.
  • Department of Neurology, UMass Chan Medical School, Worcester, MA 01605 USA.
  • Department of Radiology, UMass Chan Medical School, Worcester, MA 01605 USA.
  • Department of Radiology, UMass Chan Medical School, Worcester, MA 01605 USA; Department of Biomedical Engineering, Worcester Polytechnic Institute, Worcester, MA 01609, USA.
  • Program in Innate Immunity, Division of Infectious Diseases and Immunology, Department of Medicine, UMass Chan Medical School, Worcester, MA 01605 USA.
  • RNA Therapeutics Institute, UMass Chan Medical School, Worcester, MA 01605 USA; Department of Biochemistry and Molecular Biotechnology, UMass Chan Medical School, Worcester, MA 01605, USA. Electronic address: jonathan.w…

Förderung

  • NINDS NIH HHS
  • National Institute of Neurological Disorders and Stroke
  • Ono Pharma Foundation
  • National Institutes of Health
  • Friedreich's Ataxia Research Alliance

Zitieren

APA

Moazami, M. P., Rembetsy-Brown, J. M., Sarli, S. L., McEachern, H. R., Wang, F., Ohara, M., Wagh, A., Kelly, K., Krishnamurthy, P. M., Weiss, A., Marosfoi, M., King, R. M., Motwani, M., Gray-Edwards, H., Fitzgerald, K. A., Brown, R. H., & Watts, J. K. (2024). Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system. Molecular Therapy. https://doi.org/10.1016/j.ymthe.2024.10.024

Vancouver

Moazami MP, Rembetsy-Brown JM, Sarli SL, McEachern HR, Wang F, Ohara M, et al. Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system. Molecular Therapy. 2024. doi:10.1016/j.ymthe.2024.10.024

BibTeX
@article{Moazami2024,
  author = {Moazami, Michael P and Rembetsy-Brown, Julia M and Sarli, Samantha L and McEachern, Holly R and Wang, Feng and Ohara, Masahiro and Wagh, Atish and Kelly, Karen and Krishnamurthy, Pranathi Meda and Weiss, Alexandra and Marosfoi, Miklos and King, Robert M and Motwani, Mona and Gray-Edwards, Heather and Fitzgerald, Katherine A and Brown, Robert H and Watts, Jonathan K},
  title = {Quantifying and mitigating motor phenotypes induced by antisense oligonucleotides in the central nervous system},
  journal = {Molecular Therapy},
  year = {2024},
  doi = {10.1016/j.ymthe.2024.10.024}
}
Kostenlos starten →